Advertisement: CJBS mid banner
Advertisement mid banner S-Tech 1
Advertisement: Mogrify mid banner
Advertisement: Cambridge Network mid banner
Mid banner advertisement: BDO
Advertisement: Kao Data Centre mid banner
Advertisement: EBCam mid banner
Advertisement: Simpsons Creative
Advertisement: RSM mid banner
ARM Innovation Hub
Advertisement: partnersand mid banner
Barr Ellison Solicitors – commercial property
Advertisement: Excalibur Healthcare mid banner
Advertisement: HCR Hewitsons recruitment mid banner
7 April, 2021 - 12:05 By Tony Quested

Cambridge A-listers combine in SARS-CoV-2 move

Avacta Group plc, a developer of innovative cancer therapies and diagnostics, has agreed a global distribution deal with Cambridge neighbour Abcam to sell the group’s recently developed SARS-CoV-2 research ELISA Affimer® reagents.

Avacta has developed Affimer® reagents which can be used in a high performance ELISA laboratory test to detect the SARS-CoV-2 spike protein with high sensitivity and excellent specificity for the spike protein of the original strain of the virus and other dominant variants such as B117 (the Kent strain) and D614G.

Abcam is one of the world’s leading suppliers of high-quality biological reagents and kits which are used in a wide range of fields including drug discovery, diagnostics and basic research. 

Under the worldwide, non-exclusive distribution agreement, Abcam will enable the global research community to access Avacta’s SARS-CoV-2 spike protein Affimer® research reagents through its on-line catalogue. 

This will allow scientists around the world to perform the ELISA test in their own laboratories and support the global fight against the pandemic.

Dr Alastair Smith, chief executive of Avacta Group said: “As far as we are aware, our spike protein ELISA test is the most sensitive test of its kind and, in Abcam, we have a world-leading partner capable of maximising the commercial potential of the Affimer® reagents by making them globally available to scientists who are researching into the SARS-CoV-2 coronavirus.”

Newsletter Subscription

Stay informed of the latest news and features